ThinkSabio

$BMRN

$54.79▲ -6.4% YTD

8 SEC 13D/G filings tracked · Last updated Nov 2, 2026

Filing History
News
BMRN ▼ -6.4% - BioMarin Pharmaceutical Inc.
CP $54.79▲ -6.4%Nov 2, 2026 · ThinkSabio Blog

$BMRN - Lowers guidance…

News
BMRN ▼ -6.4% - BioMarin Pharmaceutical Inc.
CP $54.79▲ -6.4%Nov 2, 2026 · ThinkSabio Blog

$BMRN BMRN - BioMarin Reports Third Quarter 2026 Financial and Operating Results…

News
BMRN ▲ +0.5% - BioMarin Pharmaceutical Inc.
CP $56.24▲ +0.5%Oct 26, 2026 · ThinkSabio Blog

$BMRN BMRN - BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET…

News
BMRN ▼ -0.2% - BioMarin Pharmaceutical Inc.
CP $54.80▲ -0.2%Oct 9, 2026 · ThinkSabio Blog

$BMRN BMRN - BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and…

News
BMRN ▲ +0.6% - BioMarin Pharmaceutical Inc.
CP $57.54▲ +0.6%Oct 5, 2026 · ThinkSabio Blog

$BMRN BMRN - BioMarin Appoints Cara Bauer as Chief People Officer…

News
BMRN ▼ -1.1% - BioMarin Pharmaceutical Inc.
CP $57.83▲ -1.1%Oct 2, 2026 · ThinkSabio Blog

$BMRN BMRN - BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annua…

News
BMRN ▲ +0.0% - BioMarin Pharmaceutical Inc.
CP $65.23▲ +0.0%Sep 1, 2026 · ThinkSabio Blog

$BMRN BMRN - BioMarin Announces Close of the Alesta Therapeutics Acquisition…

News
BMRN ▼ -0.9% - BioMarin Pharmaceutical Inc.
CP $64.67▲ -0.9%Aug 31, 2026 · ThinkSabio Blog

$BMRN BMRN - BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Braz…